Drug Trial Radar · NCT05064878
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
87
Actual
Start
Mar 8, 2022
Primary completion
Nov 8, 2027
Study completion Nov 8, 2027
Sponsor
- Lead sponsor
- Zogenix, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 Study to examine the efficacy and safety of ZX008 in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).
Conditions
- CDKL5 Deficiency Disorder
- Generalized Tonic Clonic Seizure
- Epileptic Spasm
- Refractory Seizures
Interventions
FenfluramineDrug
Fenfluramine is supplied as an oral aqueous solution of fenfluramine hydrochloride.
PlaceboDrug
Matching fenfluramine (hydrochloride) placebo is supplied as an oral solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change from Baseline in Countable Motor Seizure Frequency (CMSF) (Part 1)Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)
- Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) (Part 2)Time frame: Up to OLE1 Treatment Period Post-Dose Safety Follow-up Visit 17 (up to 70 weeks)
- Percentage of Participants With Abnormal Physical Examination Findings (Part 2)Time frame: Up to End of Treatment (EoT)/Early Termination (ET) Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Percentage of Participants With Abnormal Neurological Examination Findings (Part 2)Time frame: Up to EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Percentage of Participants with Positive Response to Self-harm Question (Part 2)Time frame: OLE1 Treatment Period Day 1 to OLE1 Treatment Period Post-Dose Safety Follow-up Visit 17 (up to 70 weeks)
- Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 2)Time frame: Baseline (28 days), Cardiac Follow-up Visit 18 (up to 96 weeks)
- Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 2)Time frame: OLE1 Treatment Period Day 1 to EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Laboratory Parameters (Hematology) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Laboratory Parameters (Hormones) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Laboratory parameters (Chemistry) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Laboratory Parameters (Urinalysis) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Vital Signs (Blood pressure) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Vital Signs (Heart rate) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Vital Signs (Temperature) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Vital Signs (Respiratory rate) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Body Weight (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Change from Baseline in Tanner Staging (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
- Percentage of Participants with TEAEs (Part 3)Time frame: Up to OLE2 Period Post-Dose Safety Follow-up (up to 200 weeks)
- Change from Baseline in Height (Part 3)Time frame: Baseline (28 days), OLE2 Period EoT/ET Visit 23 (up to 198 weeks)
- Change from Baseline in Body Weight (Part 3)Time frame: Baseline (28 days), OLE2 Period EoT/ET Visit 23 (up to 198 weeks)
- Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 3)Time frame: Baseline (28 days), Cardiac Follow-up Visit (up to 295 weeks)
- Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 3)Time frame: OLE2 Period Day 1 to EoT/ET Visit 23 of OLE2 Period (up to 198 weeks)
Locations
46 sites in 14 countries. Site status is shown where the registry gives one.
Ep0216 154
Birmingham, Alabama
Ep0216 144
Los Angeles, California
Ep0216 101
San Francisco, California
Ep0216 173
Aurora, Colorado
Ep0216 149
Washington D.C., District of Columbia
Ep0216 157
Atlanta, Georgia
Ep0216 113
Brookline, Massachusetts
Ep0216 134
Detroit, Michigan
Ep0216 166
Chapel Hill, North Carolina
Ep0216 164
Cleveland, Ohio
Ep0216 120
Philadelphia, Pennsylvania
Ep0216 124
Memphis, Tennessee
Ep0216 171
Austin, Texas
Ep0216 2505
Linz, Austria
Ep0216 804
Brussels, Belgium
Ep0216 801
Edegem, Belgium
Ep0216 2802
Tbilisi, Georgia
Ep0216 902
Bielefeld, Germany
Ep0216 909
Kehl-kork, Germany
Ep0216 908
Kiel, Germany
Ep0216 901
Vogtareuth, Germany
Ep0216 1803
Dublin, Ireland
Ep0216 1909
Petah Tikva, Israel
Ep0216 1906
Ramat Gan, Israel
Ep0216 1904
Tel Aviv, Israel
Ep0216 1201
Florence, Italy
Ep0216 1204
Genova, Italy
Ep0216 1212
Modena, Italy
Ep0216 1206
Roma, Italy
Ep0216 1208
Roma, Italy
Ep0216 1202
Verona, Italy
Ep0216 1512
Hiroshima, Japan
Ep0216 1505
Niigata, Japan
Ep0216 1518
Omura-shi, Japan
Ep0216 1502
Shizuoka, Japan
Ep0216 1401
Zwolle, Netherlands
Ep0216 2104
Lisbon, Portugal
Ep0216 2105
Porto, Portugal
Ep0216 1103
Barcelona, Spain
Ep0216 1117
Madrid, Spain
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.